Sei Investments Co. Lowers Stake in Ascendis Pharma A/S (NASDAQ:ASND)

Sei Investments Co. trimmed its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 3.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 263,582 shares of the biotechnology company's stock after selling 10,165 shares during the period. Sei Investments Co. owned approximately 0.43% of Ascendis Pharma A/S worth $36,287,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of ASND. Legato Capital Management LLC boosted its position in shares of Ascendis Pharma A/S by 7.5% during the fourth quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company's stock valued at $264,000 after buying an additional 134 shares during the last quarter. Jones Financial Companies Lllp lifted its stake in Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after acquiring an additional 197 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Ascendis Pharma A/S during the 3rd quarter worth $30,000. GAMMA Investing LLC grew its stake in shares of Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 214 shares in the last quarter. Finally, Blue Trust Inc. raised its holdings in shares of Ascendis Pharma A/S by 415.2% in the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 328 shares during the last quarter.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on ASND shares. Morgan Stanley set a $180.00 price objective on shares of Ascendis Pharma A/S in a research report on Tuesday, February 18th. Cantor Fitzgerald increased their price target on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a research report on Tuesday, February 25th. The Goldman Sachs Group upped their price objective on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. UBS Group initiated coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They set a "buy" rating and a $196.00 target price on the stock. Finally, JPMorgan Chase & Co. raised their price objective on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an "overweight" rating in a report on Tuesday, March 18th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of "Moderate Buy" and a consensus target price of $204.64.

Ascendis Pharma A/S Stock Down 4.1 %

ASND traded down $6.95 during trading on Tuesday, reaching $161.04. 402,861 shares of the company were exchanged, compared to its average volume of 459,601. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $169.37. The company's 50-day moving average is $142.64 and its two-hundred day moving average is $136.45. The company has a market cap of $9.77 billion, a price-to-earnings ratio of -22.68 and a beta of 0.62.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64. Equities analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.